Pharmaceuticals
Pierre Fabre pursues its commitment against rare diseases in the pediatric, oncology and dermatology fields.
RARE DISEASE DAY – February 28th, 2023 The diseases are rare, but they impact a lot of people : nearly 300 million people are affected worldwide1. CASTRES, France, Feb. 6, 2023 /PRNewswire/ -- International Rare Disease Day® will be held onFebruary 28, an opportunity for the Pierre Fabre Group t...
2023-02-06 18:00
3385
Boehringer Ingelheim Philippines is awarded Top Employer for the 5th year in a row
* Boehringer Ingelheim is one of 15 global Top Employers worldwide * Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® * Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition M...
2023-02-06 08:00
2889
Qiming Venture Partners Backed Structure Therapeutics Successfully Debuts on Nasdaq
SHANGHAI, Feb. 4, 2023 /PRNewswire/ -- Qiming Venture Partners' portfolio company Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical stage global biopharmaceutical company focusing on novel oral small molecule therapeutics, successfully debuts on Nasdaq on February 3 Beijing Time. It issued a...
2023-02-04 14:45
9100
Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer
NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointedRoger Sidhu, M.D., as Chief Medical Officer. Dr. Sidhu is a seasoned lea...
2023-02-03 22:00
6596
Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
Landmark Agreement for New Tuberculosis Treatment SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based inSouth Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, ...
2023-02-03 14:34
3406
Servier full year 2021/22 results confirm the transformation trajectory of the Group
* Consolidated sales revenue of €4.876 billion, up 9.8% (+6.6% at CERi), driven by strong growth in international sales * Sales revenue for brand-name medicines reached €3.694 billion, up 12.5% (+8.9% at CERi), and €1.182 billion for generics, up 2.0% (stable at CERi) * Important development...
2023-02-02 14:30
2635
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)
SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Invivoscribe is pleased to announce the appointment ofMasato Sasaki as General Manager of LabPMM GK, our reference laboratory inJapan. Mr. Sasaki brings a wealth of scientific experience with him as he served at Illumina K.K. (Japan) as a leader on their cl...
2023-02-02 05:00
3468
Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that it is advancing the clinical development of...
2023-02-01 15:00
4916
Innovation Deficit: Funds for Neglected Diseases like TB are Falling Short
NEW YORK, Jan. 31, 2023 /PRNewswire/ -- The 2022 G-FINDER Report, released today, reveals that for the year 2021, global funding for the development of critical new health technologies to overcome the world's deadliest neglected diseases remained woefully inadequate and largely stagnant. Specific...
2023-01-31 21:30
2585
Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed t...
2023-01-31 17:40
4571
Delivery of 170,000 Bottles of Azvudine Tablets During Spring Festival to Help Rural Areas Weather the Epidemic
HONG KONG, Jan. 31, 2023 /PRNewswire/ -- In response to the infection peak season of COVID-19 in rural areas that may be brought about by people returning home during Chinese New Year, Fosun Foundation announced on9 January 2023 the cooperation with Fosun Pharma and Genuine Biotech to donateRMB10...
2023-01-31 16:10
4518
Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region
* Daewoong Pharmaceutical to receive up to $76M upfront and development milestone payment plus a double-digit royalties on Net Sales * CS Pharmaceuticals will receive exclusive rights for development and commercialization of Bersiporocin for the treatment of IPF and other respiratory indica...
2023-01-31 14:43
6179
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China
HANGZHOU, China and SAN FRANCISCO, Jan. 31, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of patient dosing in Phase 3 clinical tr...
2023-01-31 08:00
3899
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
* ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. * ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. * ORSERDU is the first endocrine innovation in more than 20 years, specif...
2023-01-30 20:39
3622
Kalbe Consumer Health Crowned Winner at the Asia Pacific Enterprise Awards 2022 Regional Edition
SINGAPORE, Jan. 27, 2023 /PRNewswire/ -- Enterprise Asia, the organizer of the Asia Pacific Enterprise Awards (APEA) 2022 Regional Edition, is pleased to recognize 25 exemplary business leaders and enterprises acrossAsia which excelled and showcased unparalleled resilience and growth despite theC...
2023-01-30 11:26
3308
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor Pimicotinib（ABSK021）has been granted the breakthrough therapy designation from FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients...
2023-01-30 11:00
5813
Malaysian Society of Plastic and Reconstructive Surgery to host extensive networking and learning event for plastic surgeons and residents
The two-day symposium will have its core focus on cosmetic breast surgery, with two live surgical demonstrations. CPD points to be given to all participating surgeons. KUALA LUMPUR, Malaysia, Jan. 27, 2023 /PRNewswire/ -- The Malaysian Society for Plastic and Reconstructive Surgery (MSPRS) is s...
2023-01-27 08:00
5078
Fosun International Wins Platinum Award at The Asset ESG Corporate Awards 2022
HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX: 00656) was informed byThe Asset, the renowned international asset management and investment magazine, that Fosun has garnered the Platinum Award at The Asset ESG Corporate Awards 2...
2023-01-26 14:59
5109
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea
"Expected to change GERD drug market landscape" * Application for product approval of Fexuclue, a new drug for gastroesophageal reflux disease (GERD), has been completely submitted toColombia ,Vietnam, and Saudi Arabia * NDA submissions in 11 countries completed in the shortest time among K...
2023-01-26 09:14
3814
Malaysia Healthcare Partners with AirAsia
Cambodian Passengers Can Kickstart 2023 with Wellness Travel to Malaysia PHNOM PENH, Cambodia, Jan. 25, 2023 /PRNewswire/ -- In its pursuit to providing accessible preventive healthcare and wellness options for global citizens, Malaysia Healthcare Travel Council (MHTC) partners with AirAsia, off...
2023-01-25 14:05
4970
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 278 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 269 media titles]
2026-10-14 18:01Ampotech and Buskowitz Energy Collaborate to Deliver Integrated Energy Solutions Combining Energy Efficiency, Solar and Battery Storage
[Picked up by 263 media titles]
2026-10-14 09:30
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
15332
LEIFRAS Co., Ltd. Reports First Half of Fiscal Year 2026 Financial Results
2026-10-08 09:50
13390
XPENG G9L Completes First Production Trial in Europe
2026-10-08 07:33
12916
